

		Total	PBO n	PBO % with events	OCR 600 mg n	OCR 600 mg % with events	HR	95% CI	p value
Both hands	ITT	732	244	27·0	488	17·0	0·56	0·41–0·78	<0·001
	BL 9HPT time								
	Abnormal	434	137	34·3	297	21·5	0·56	0·38–0·82	0·003
	Normal	298	107	17·8	191	9·9	0·51	0·27–0·97	0·039
	BL EDSS								
	≥6	220	81	42·0	139	26·6	0·62	0·39–1·0	0·052
	<6	511	163	19·6	348	13·2	0·60	0·38–0·94	0·027
Better hand	ITT	732	244	25·4	488	20·1	0·72	0·53–1·0	0·046
	BL 9HPT time								
	Abnormal	344	112	29·5	232	26·7	0·83	0·54–1·27	0·38
	Normal	388	132	22·0	256	14·1	0·60	0·37–0·98	0·042
	BL EDSS								
	≥6	220	81	35·8	139	28·1	0·73	0·45–1·2	0·22
	<6	511	163	20·2	348	17·0	0·79	0·51–1·20	0·27
Worse hand	ITT	732	244	26·6	488	18·4	0·63	0·46–0·87	0·005
	BL 9HPT time								
	Abnormal	513	168	32·1	345	21·4	0·61	0·43–0·86	0·006
	Normal	219	76	14·5	143	11·2	0·75	0·34–1·63	0·46
	BL EDSS								
	≥6	220	81	43·2	139	25·9	0·54	0·33–0·86	0·010
	<6	511	163	18·4	348	15·5	0·79	0·50–1·23	0·30

Figure S1. Time to 12-week CP (≥20% increase) in 9HPT time in the ITT population and subgroups of patients with abnormal/normal 9HPT times at baseline, and patients with baseline EDSS <6 and ≥6.

HR derived from a Cox proportional hazards model stratified by region (USA vs rest of world) and age (≤45, >45 years).

9HPT, Nine-Hole Peg Test; BL, baseline; CP, confirmed progression; EDSS, Expanded Disability Status Scale; HR, hazard ratio; ITT, intention-to-treat; OCR, ocrelizumab; PBO, placebo.



Figure S2. Time to 12- and 24-week CP (≥20% increase) in 9HPT time in the ITT population using the "best of 2" calculation method.
9HPT, Nine-Hole Peg Time; CP, confirmed progression; HR, hazard ratio; ITT, intention-to-treat.



	Threshold of Progression	Total	PBO n	PBO % with events	OCR 600 mg n	OCR 600 mg % with events	HR	95% CI	p value
Both hands	≥20%	732	244	27·0	488	17·0	0·56	0·41–0·78	<0·001
	≥25%	732	244	23·8	488	13·7	0·52	0·37–0·74	<0·001
	≥30%	732	244	19·7	488	11·1	0·50	0·34–0·74	<0·001
	≥35%	732	244	16·8	488	9·4	0·51	0·34–0·78	0·002
Better hand	≥20%	732	244	25·4	488	20·1	0·72	0·53–0·99	0·046
	≥25%	732	244	20·5	488	15·6	0·70	0·49–1·00	0·048
	≥30%	732	244	18·0	488	13·5	0·69	0·47–1·01	0·059
	≥35%	732	244	14·3	488	11·3	0·74	0·48–1·12	0·16
Worse hand	≥20%	732	244	26·6	488	18·4	0·63	0·46–0·87	0·005
	≥25%	732	244	24·2	488	13·7	0·52	0·37–0·74	<0·001
	≥30%	732	244	22·1	488	12·1	0·50	0·34–0·72	<0·001
	≥35%	732	244	20·1	488	10·9	0·50	0·34–0·73	<0·001

Figure S3. Time to more-severe 12-week CP (≥25%, ≥30%, and ≥35% increase) in 9HPT time in the ITT population.

HR derived from a Cox proportional hazards model stratified by region (USA vs rest of world) and age (≤45, >45 years). No adjustments were made to account for multiplicity of testing.

9HPT, Nine-Hole Peg Test; BL, baseline; CP, confirmed progression; EDSS, Expanded Disability Status Scale; HR, hazard ratio; ITT, intention-to-treat; OCR, ocrelizumab; PBO, placebo.